GlassScriptPhysician profile
John-Paul Berauer
NPI 1154640860
$2,773.35
in general payments reported to CMS, 2019-2025
17 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 84% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $619 · 2024: $779 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $612.00 | 2024-2025 | Livmarli |
| Regeneron Healthcare Solutions, INC. | $414.95 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $313.14 | 2023-2025 | Sucraid, Sucraid |
| Albireo Pharma, INC. | $277.49 | 2023-2024 | Bylvay |
| Cook Medical LLC | $187.84 | 2025 | Hemospray, Fusion |
| Ipsen Biopharmaceuticals, INC | $175.97 | 2024-2025 | Bylvay, Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $173.10 | 2022-2025 | Eohilia |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Genzyme Corporation | $113.09 | 2023-2024 | |
| Olympus America INC. | $77.61 | 2023-2025 | Evis Exera III Xenon Light Source, Single Use Electrosurgical Snare Sd-400 |
| Rhythm Pharmaceuticals, INC. | $70.75 | 2023 | Imcivree |
| Janssen Biotech, INC. | $55.07 | 2023-2025 | Stelara, Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.63 | 2023-2024 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $39.49 | 2023 | |
| Abbvie INC. | $39.36 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $34.76 | 2023-2024 | Erbe Vio3 Apc3, Vio3 Apc3 |
| Aimmune Therapeutics, INC. | $21.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John-Paul Berauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.